Ezetimibe/rosuvastatin

Last updated

Ezetimibe/rosuvastatin
Ezetimibe and rosuvastatin.svg
Ezetimibe (top) and rosuvastatin (bottom)
Combination of
Ezetimibe Hypolipidemic agent
Rosuvastatin Statin
Clinical data
Trade names Ridutrink, Roszet, others
AHFS/Drugs.com Multum Consumer Information
License data
Pregnancy
category
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [9]

Contents

The combination was approved for medical use in the United States in March 2021. [4]

Medical uses

Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. [10]

Pharmacology

Ezetimibe/rosuvastatin combines two lipid-lowering therapies.

References

  1. 1 2 "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 29 March 2022. Retrieved 25 March 2021.
  2. ↑ "EZESTAT COMPOSITE PACK (Pharmacor Pty Ltd)". Department of Health and Aged Care . Archived from the original on 18 March 2023.
  3. 1 2 3 "DailyMed - Roszet- rosuvastatin and ezetimibe tablet Roszet (- rosuvastatin and ezetimibe tablet". dailymed.nlm.nih.gov. Archived from the original on 14 August 2022. Retrieved 14 January 2024.
  4. 1 2 "Roszet: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 March 2021.
  5. ↑ "Ezetimibe/rosuvastatin: List of nationally authorised medicinal products" (PDF). European Medicines Agency (EMA). 21 March 2018. PSUSA/00010271/201707. Retrieved 17 February 2020.
  6. ↑ "Ridutrin SmPC" (PDF). Medicines Data Bank. 30 May 2019. Archived (PDF) from the original on 18 February 2020. Retrieved 17 February 2020.
  7. ↑ Willihnganz MJ, Gurevitz SL, Clayton BD (November 2021). "HMG-CoA Reductase Inhibitor Combination Products". Clayton's Basic Pharmacology for Nurses - E-Book. Elsevier Health Sciences. p. 344. ISBN   978-0-323-81258-0.
  8. ↑ "Rosuzet Composite Pack". NPS MedicineWise. 8 January 2020. Archived from the original on 18 February 2020. Retrieved 17 February 2020.
  9. ↑ "Rosuvastatin international". Drugs.com. 3 February 2020. Archived from the original on 18 February 2020. Retrieved 17 February 2020.
  10. ↑ Sharretts J (23 March 2021). "NDA Approval Letter for Roszet (rosuvastatin and ezetimibe)" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 7 April 2023. Retrieved 25 March 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.